GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted Revenue per Share

Takara Bio (TSE:4974) Cyclically Adjusted Revenue per Share : 円400.79 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Takara Bio's adjusted revenue per share for the three months ended in Mar. 2025 was 円130.930. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円400.79 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Takara Bio's average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Takara Bio was 14.40% per year. The lowest was 6.50% per year. And the median was 10.70% per year.

As of today (2025-05-23), Takara Bio's current stock price is 円755.00. Takara Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was 円400.79. Takara Bio's Cyclically Adjusted PS Ratio of today is 1.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takara Bio was 14.83. The lowest was 1.89. And the median was 8.52.


Takara Bio Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Takara Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Cyclically Adjusted Revenue per Share Chart

Takara Bio Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 254.20 295.42 350.47 373.80 400.79

Takara Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 373.80 379.96 386.09 394.45 400.79

Competitive Comparison of Takara Bio's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Takara Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takara Bio's Cyclically Adjusted PS Ratio falls into.


;
;

Takara Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takara Bio's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=130.93/111.1000*111.1000
=130.930

Current CPI (Mar. 2025) = 111.1000.

Takara Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 47.843 98.400 54.018
201509 62.251 98.500 70.214
201512 61.861 98.100 70.059
201603 74.932 97.900 85.035
201606 52.369 98.100 59.309
201609 57.243 98.000 64.895
201612 61.836 98.400 69.817
201703 72.499 98.100 82.106
201706 52.776 98.500 59.527
201709 64.535 98.800 72.569
201712 70.755 99.400 79.083
201803 80.272 99.200 89.901
201806 73.471 99.200 82.285
201809 70.780 99.900 78.715
201812 70.738 99.700 78.826
201903 82.655 99.700 92.106
201906 71.835 99.800 79.969
201909 64.775 100.100 71.893
201912 67.333 100.500 74.435
202003 83.104 100.300 92.052
202006 57.617 99.900 64.077
202009 86.824 99.900 96.558
202012 100.950 99.300 112.946
202103 137.332 99.900 152.729
202106 126.828 99.500 141.614
202109 135.190 100.100 150.046
202112 117.161 100.100 130.036
202203 183.022 101.100 201.125
202206 117.112 101.800 127.811
202209 153.510 103.100 165.422
202212 229.363 104.100 244.786
202303 148.949 104.400 158.508
202306 76.203 105.200 80.477
202309 82.547 106.200 86.356
202312 88.178 106.800 91.728
202403 114.448 107.200 118.612
202406 70.572 108.200 72.463
202409 93.545 108.900 95.435
202412 79.137 110.700 79.423
202503 130.930 111.100 130.930

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Takara Bio  (TSE:4974) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takara Bio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=755.00/400.79
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Takara Bio was 14.83. The lowest was 1.89. And the median was 8.52.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Takara Bio Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Takara Bio's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio Headlines

No Headlines